ea0029p687 | Diabetes | ICEECE2012
, Furuya F.
, Kobayashi T.
Introduction: A potent and selective DPP-4 inhibitor improves islet function by enhancing α- and β-cell responsiveness to glucose in the diabetic patients. Renal impairment is a common complication of type 2 diabetes mellitus (T2DM). Vildagliptin is used to treat T2DM as monotherapy or in combination with other antidiabetic drugs, since that it efficiently decreases glycated hemoglobin (HbA1c) values. Additionally, vildagliptin has been shown to be safe in patients w...